The economic effect of extracorporeal membrane oxygenation to support adults with severe respiratory failure in Brazil: a hypothetical analysis

Abstract

Objective To analyze the cost-utility of using extracorporeal oxygenation for patients with severe acute respiratory distress syndrome in Brazil.Methods A decision tree was constructed using databases from previously published studies. Costs were taken from the average price paid by the Brazilian Unified Health System (Sistema Único de Saúde; SUS) over three months in 2011. Using the data of 10,000,000 simulated patients with predetermined outcomes and costs, an analysis was performed of the ratio between cost increase and years of life gained, adjusted for quality (cost-utility), with survival rates of 40 and 60% for patients using extracorporeal membrane oxygenation.Results The decision tree resulted in 16 outcomes with different life support techniques. With survival rates of 40 and 60%, respectively, the increased costs were R$=-301.00/-14.00, with a cost of R$=-30,913.00/-1,752.00 paid per six-month quality-adjusted life-year gained and R$=-2,386.00/-90.00 per quality-adjusted life-year gained until the end of life, when all patients with severe ARDS were analyzed. Analyzing only patients with severe hypoxemia (i.e., a ratio of partial oxygen pressure in the blood to the fraction of inspired oxygen <100mmHg), the increased cost was R$=-5,714.00/272.00, with a cost per six-month quality-adjusted life-year gained of R$=-9,521.00/293.00 and a cost of R$=-280.00/7.00 per quality-adjusted life-year gained.Conclusion The cost-utility ratio associated with the use of extracorporeal membrane oxygenation in Brazil is potentially acceptable according to this hypothetical study.

Health-related quality of life, one-year costs and economic evaluation in extracorporeal membrane oxygenation in critically ill adults

“…The hypothetical study from Brazil using epidemiological data and a Markov model showed a negative cost per QALY ratio with a reduction in ICU stay associated with ECMO in a scenario with a 40% survival. [29]. In a study from Finland in patients with VA ECMO median costs per QALY were $9389 with the highest costs per QALY for patients post-heart transplant.…”

Establishing an ECMO program in a developing country: challenges and lessons learned

“…Several reports have shown that ECMO is favorable when considering cost/life-year calculation and is justified on cost-utility basis. [9][10][11][12] The ELSO registry stated that the cost effectiveness of ECMO support for fewer than six patients per year should be taken into consideration. In AUBMC, 12 patients were supported with ECMO within a period of 26 months.…”

Evaluation of the discrimination and calibration of predictive scores of mortality in ECMO for patients with COVID‐19

“…Additionally, the cost of this technology in developing countries has had significant repercussions, 12 especially during the COVID‐19 pandemic. The extended use of ECMO requires highly specialized staff, and equipment which increases resource use and hospital costs 8 .…”